Page 5 of 8
ACS Medicinal Chemistry Letters
Songjiang
Science
District(No.16SJGG20),
and Technology
Ningbo
Bureau
antagonists as anti-hypertension drugs. Bioorg.
1
2
Med. Chem. 2016, 24, 2023 - 2031.
3
4
5
6
7
8
9
[8] Kim, S.; Ohta, K.; Hamaguchi, A.; Omura, T.;
Yukimura, T.; Miura, K.; Inada, Y.; Ishimura, Y.;
Chatani, F.; Wao, H. I. Angiotensin II type I
receptor antagonist inhibits the gene expression of
transforming growth factor-β1 and extracellular
matrix in cardiac and vascular tissues of
hypertensive rats. J. Pharmacol. Exp. Ther. 1995,
273, 509 - 515.
(No.2017BS1CA01008).
REFERENCES
[1] Michal, B.; Barbara, M.; Magdalena, T.;
Martek, T.; Anna, J.; Patryk, R.; Elzbieta, S.
Hypertension and chronic inhibition of
endocannabinoid degradation modify the
endocannabinoid system and redox balance in rat
heart and plasma. Prostaglandins and Other Lipid
Mediators. 2018, 138, 54-63.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[9] Chiu, A. T.; McCall, D. E.; Price, W. A.; Wong,
P. C.; Carini, D. J.; Duncia, J. V.; Wexler, R; Yoo.
S.; Johnson, A.; Timmermans, P. B. Nonpeptide
angiotensin II receptor antagonists. VII. Cellular
and biochemical pharmacology of DuP 753, an
orally active antihypertensive agent. J. Pharmacol.
Exp. Ther. 1990, 252, 711 - 718.
[2] Habli, M.; Clifford, C.; Brady, T. M.;
Rodriguez, Z.; Eschenbacher, M.; Wu, Malcolm.;
DeFranco, E.; Gresh, J.; Kamath-Rayne, B. D.;
Antenatal exposure to nonsteroidal anti-
inflammatory drugs and risk of neonatal
hypertension. J. Clin. Hypertension. 2018, 20,
1334-1341.
[10] Zhu, W.; Da, Y.; Wu, D.; Zheng, H.; Zhu, L.;
Wang, L.; Yan, Y.; Chen, Z. L. Design, synthesis
and biological evaluation of new 5-nitro
benzimidazole derivatives as AT1 antagonists with
anti-hypertension activities. Bioorg. Med. Chem.
2014, 22, 2294 - 2302.
[3] Pershadsingh, H. A. New generation
angiotensin II type 1 receptor angiotensin that
selectively modulate peroxisome proliferator -
activated Receptor-y. Drug Dev. Res. 2006, 67,
687 - 697.
[11] Kalaitzidis, R.; Bakris, G. Management of
hypertension in patients with diabetes: the place of
angiotensin-II receptor blockers. Diabetes, Obes.
Metab. 2009, 11, 757 - 769.
[4] Naik, P.; Murumkar, P.; Giridhar, R.; Yadav.
M, R. Angiotensin II receptor type 1 (AT1)
selective nonpeptidic antagonists - A perspective.
Bioorg. Med. Chem. 2010, 18, 8418 - 8456.
[5] Sealey, J. E.; Laragh, J. H. The renin-
angiotensin-aldosterone system for normal
regulation of blood pressure and sodium and
potassium homeostasis. In: J. H. Laragh, B. M.
Brenner (Eds). Hypertension: Pathophysiology,
Diagnosis and Management, Raven Press, New
York, 1990, pp. 1287 - 1317.
[12] Tahsin, F. K.; Andreas, G.; Tzakos,; Thomas,
M. Rational drug design and synthesis of
molecules targeting the angiotensin II type 2
receptors. Molecules. 2015, 20, 3868-3897.
[13] Uwe J, R.; Gerhard, M.; Berthold, Narr.; Kai
M, H.; Helmut, W.; Michael, E.; Jacobus, C. A. M.;
Wolfgang, W.; Norbert, H. H; 6-Substituted
benzimidazoles as new nonpeptide angiotensin II
receptor antagonists: synthesis, biological activity,
and structure-activity relationships. J. Med. Chem.
1993, 36, 4040 - 4051.
[6] Hong. K.; Kim, C; Lee, S.; Yoo, S. E. The in
vitro pharmacological profile of KR31080, a
nonpeptide AT1 receptor antagonist. Fundam.
Clin. Pharmacol. 1998, 12, 64 - 69.
[14] Zhang, J.; Wang, J.; Yu, W.; Zhou, Z.; Tao,
W; Wang, Y.; Xue, W.; Xu, D.; Hao, L.; Han, X.;
Fei, F.; Liu, T.; Liang, A. Nonpeptidic angiotensin
[7] Bao, X.; Zhu, W.; Zhang, R.; Wen, C.; Wang,
L.; Yan, Y.; Tang, H.; Chen, Z. L. Synthesis and
evaluation of novel angiotensin II receptor 1
ACS Paragon Plus Environment